Multi-targeted tyrosine kinase inhibitor combined with PD-L1 inhibitor

This page covers all Multi-targeted tyrosine kinase inhibitor combined with PD-L1 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGFR, FGFR, PDGFR, c-Kit (anlotinib); PD-L1 (benmelstobart).

Targets

VEGFR, FGFR, PDGFR, c-Kit (anlotinib); PD-L1 (benmelstobart)

Phase 3 pipeline (1)

• anlotinib combined with benmelstobart · The First Affiliated Hospital of Zhengzhou University · Oncology
  Anlotinib is a multi-targeted tyrosine kinase inhibitor combined with benmelstobart (an anti-PD-L1 monoclonal antibody) to block tumor angiogenesis and enhance anti-tumor immune response.

Patent intelligence

• multi targeted tyrosine kinase inhibitor combined with pd l1 inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates